NZ702191A - Nalmefene for reduction of alcohol consumption in specific target populations - Google Patents

Nalmefene for reduction of alcohol consumption in specific target populations

Info

Publication number
NZ702191A
NZ702191A NZ702191A NZ70219113A NZ702191A NZ 702191 A NZ702191 A NZ 702191A NZ 702191 A NZ702191 A NZ 702191A NZ 70219113 A NZ70219113 A NZ 70219113A NZ 702191 A NZ702191 A NZ 702191A
Authority
NZ
New Zealand
Prior art keywords
nalmefene
reduction
alcohol consumption
specific target
target populations
Prior art date
Application number
NZ702191A
Other languages
English (en)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladström
Christine Persson
Didier Meulien
Per Sørensen
Thomas Jon Jensen
Jette Buch Østergaard
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ702191(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of NZ702191A publication Critical patent/NZ702191A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NZ702191A 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations NZ702191A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15
PCT/EP2013/063461 WO2014001427A1 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Publications (1)

Publication Number Publication Date
NZ702191A true NZ702191A (en) 2017-06-30

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ702191A NZ702191A (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP2866808B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK2866808T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2950492T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20230762T8 (enExample)
HU (4) HUE063313T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT2866808T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3345604T3 (enExample)
PT (3) PT3345604T (enExample)
RS (2) RS57046B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI3138564T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
CA2946698A1 (en) 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
EA019331B1 (ru) 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
AU2011325563B2 (en) 2010-11-05 2015-08-20 H. Lundbeck A/S Method for the manufacturing of naltrexone
CA2829280C (en) 2011-03-31 2016-05-24 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Compositions of opioid antagonists and their use for treating scleroderma
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
ES2663532T3 (es) 2018-04-13
JP6857684B2 (ja) 2021-04-14
PL3345604T3 (pl) 2023-08-28
ES2609122T3 (es) 2017-04-18
SI3138564T1 (en) 2018-04-30
EP2866808A1 (en) 2015-05-06
RU2014151156A (ru) 2016-08-20
ME02587B (me) 2017-06-20
CY1126140T1 (el) 2023-11-15
ES3014068T3 (en) 2025-04-16
SMT201800164T1 (it) 2018-07-17
SMT201600471T1 (it) 2017-03-08
SMT201600471B (it) 2017-03-08
EA201492152A1 (ru) 2015-11-30
HRP20230762T8 (hr) 2024-01-05
MX2014015488A (es) 2015-03-06
RS55456B1 (sr) 2017-04-28
IL236035A0 (en) 2015-01-29
EP3345604A1 (en) 2018-07-11
US20140005216A1 (en) 2014-01-02
HRP20250329T1 (hr) 2025-05-09
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
PT2866808T (pt) 2017-01-03
US9642849B2 (en) 2017-05-09
HK1255683A1 (en) 2019-08-23
EP4223296A3 (en) 2023-09-27
JP2019163275A (ja) 2019-09-26
LT2866808T (lt) 2017-01-10
CY1118579T1 (el) 2017-07-12
AU2013283281A1 (en) 2014-12-11
DK3138564T3 (en) 2018-03-26
JP2015521647A (ja) 2015-07-30
HUE063313T2 (hu) 2024-01-28
HUE031110T2 (en) 2017-06-28
EP3345604B1 (en) 2023-06-07
UA114199C2 (uk) 2017-05-10
HUE070621T2 (hu) 2025-06-28
SI3345604T1 (sl) 2023-08-31
DK2866808T3 (en) 2017-01-16
LT3138564T (lt) 2018-04-10
PL3138564T3 (pl) 2018-06-29
FI3345604T3 (fi) 2023-07-28
KR20150023396A (ko) 2015-03-05
MY166914A (en) 2018-07-24
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
MX371373B (es) 2020-01-28
US10034874B2 (en) 2018-07-31
CA2874703C (en) 2022-08-23
CO7160087A2 (es) 2015-01-15
WO2014001427A1 (en) 2014-01-03
EP4541421A3 (en) 2025-06-18
JP6258933B2 (ja) 2018-01-10
US20180028526A1 (en) 2018-02-01
HUE036272T2 (hu) 2018-06-28
EP4223296A2 (en) 2023-08-09
CN104411313A (zh) 2015-03-11
CA2874703A1 (en) 2014-01-03
JP2018039810A (ja) 2018-03-15
EP4541421A2 (en) 2025-04-23
DK3345604T3 (da) 2023-07-24
US20140005217A1 (en) 2014-01-02
PL2866808T3 (pl) 2017-04-28
PT3138564T (pt) 2018-04-03
AU2013283281B2 (en) 2017-04-20
EP3138564B1 (en) 2018-01-31
RS57046B1 (sr) 2018-05-31
ES2950492T3 (es) 2023-10-10
PL4223296T3 (pl) 2025-04-14
BR112014032555A2 (pt) 2017-06-27
EA029908B1 (ru) 2018-05-31
EP3138564A1 (en) 2017-03-08
CL2014003484A1 (es) 2015-02-27
HRP20180363T1 (hr) 2018-04-20
EP4223296B1 (en) 2025-01-29
SG11201408704WA (en) 2015-01-29
IL236035B (en) 2018-12-31
HK1208185A1 (en) 2016-02-26
HRP20230762T1 (hr) 2023-10-13
CY1120097T1 (el) 2018-12-12
LT3345604T (lt) 2023-08-10
ZA201409525B (en) 2016-08-31
PT3345604T (pt) 2023-07-17
ME03030B (me) 2018-10-20
HRP20161717T1 (hr) 2017-02-10
EP4223296C0 (en) 2025-01-29
EP2866808B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
AU338329S (en) Hinge
AU341123S (en) Oil pan
AU342950S (en) Utility pump
AU342351S (en) Automobile
CY1126140T1 (el) Ναλμεφενη για τη μειωση της καταναλωσεως αλκοολης σε συγκεκριμενους πληθυσμους στοχους
AU342936S (en) Insole
GB201102108D0 (en) Diagnostic method
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
AU338318S (en) Latch
MX2013005759A (es) Metodos para detectar bajo grado de inflamacion.
AU344993S (en) Toilet pan
CA144989S (en) Adapter for firearms
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия
AU349260S (en) Refill for device
AU341442S (en) Soles
AU341441S (en) Soles
AU340249S (en) Soles
AU340248S (en) Soles

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2019 BY CPA GLOBAL

Effective date: 20180510

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2020 BY CPA GLOBAL

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2021 BY CPA GLOBAL

Effective date: 20200514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2022 BY CPA GLOBAL

Effective date: 20210513

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2023 BY CPA GLOBAL

Effective date: 20220512

LAPS Patent lapsed